Detailansicht

Wissensnetz

Person

Johannes Schetelig (1968-)

Arzt

Name	Johannes Schetelig
Zeit	1968- (Lebensdaten)
Ort	Dresden (Wirkungsort) Deutschland
Akademischer Grad bzw. Titel	Prof. Dr. med.
Beruf	Arzt (charakteristischer Beruf)
Beziehung	Medizinische Klinik und Poliklinik I (Dresden)
Weitere Angaben	Diss. Fachbereich Humanmedizin; Facharzt für Innere Medizin, Hämatologie/internistische Onkologie, Schwerpunkt: Multiples Myelom, akute Leukämien; Oberarzt in der Medizinischen Klinik I, Universitätsklinikum Carl Gustav Carus Dresden
Datensatztyp	Person
GND-Nummer	120026953
Datensatz-ID	120026953
Beteiligt an alle anzeigen How risky is a second allogeneic stem cell transplantation? Correction: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML : Residual Morphological Blast Count Determines the Risk of Relapse Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation - a national multicenter study How risky is a second allogeneic stem cell transplantation? Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations Outcomes of haploidentical transplants with PT-CY versus 10/10 MUD transplants with ATG in Germany Perturbations of mesenchymal stromal cells after allogeneic hematopoietic cell transplantation predispose for bone marrow graft- versus-host-disease Potential of TCR sequencing in graft-versus-host disease Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study Alterations of cohesin complex genes in acute myeloid leukemia : differential co-mutations, clinical presentation and impact on outcome Case Report: ANXA2 Associated Life-Threatening Coagulopathy With Hyperfibrinolysis in a Patient With Non-APL Acute Myeloid Leukemia Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification Fascia training in patients undergoing allogeneic hematopoietic cell transplantation—a pilot study Potential of TCR sequencing in graft-versus-host disease Klonale Hämatopoese – Bedeutung für die Zelltherapie Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD Untersuchung genetischer und epigenetischer Alterationen sowie daraus abgeleiteter personalisierter Therapievorschläge beim CUP-Syndrom Development of a novel system for in vivo cell lineage tracing by CRISPR/Cas9-mediated genetic barcoding Loss-of-function mutations of BCOR are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemia Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial Stem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study Modified DHAP regimen in the salvage treatment of refractory or relapsed lymphomas Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effects Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial) Karyotype complexity and prognosis in acute myeloid leukemia Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST)

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Johannes Schetelig (1968-)

How risky is a second allogeneic stem cell transplantation?

Correction: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT

Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence

Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT

Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML : Residual Morphological Blast Count Determines the Risk of Relapse

Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation - a national multicenter study

How risky is a second allogeneic stem cell transplantation?

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

Outcomes of haploidentical transplants with PT-CY versus 10/10 MUD transplants with ATG in Germany

Perturbations of mesenchymal stromal cells after allogeneic hematopoietic cell transplantation predispose for bone marrow graft- versus-host-disease

Potential of TCR sequencing in graft-versus-host disease

Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies

Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study

Alterations of cohesin complex genes in acute myeloid leukemia : differential co-mutations, clinical presentation and impact on outcome

Case Report: ANXA2 Associated Life-Threatening Coagulopathy With Hyperfibrinolysis in a Patient With Non-APL Acute Myeloid Leukemia

Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

Fascia training in patients undergoing allogeneic hematopoietic cell transplantation—a pilot study

Potential of TCR sequencing in graft-versus-host disease

Klonale Hämatopoese – Bedeutung für die Zelltherapie

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis

Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD

Untersuchung genetischer und epigenetischer Alterationen sowie daraus abgeleiteter personalisierter Therapievorschläge beim CUP-Syndrom

Development of a novel system for in vivo cell lineage tracing by CRISPR/Cas9-mediated genetic barcoding

Loss-of-function mutations of BCOR are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemia

Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia

Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia

Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial

Stem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS

A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy

Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia

Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey

A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy

Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

Modified DHAP regimen in the salvage treatment of refractory or relapsed lymphomas

Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning

Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis

Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia

Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effects

Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

Karyotype complexity and prognosis in acute myeloid leukemia

Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST)